Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA to scour medical literature for potential safety concerns from popular drugs

This article was originally published in SRA

Executive Summary

The European Medicines Agency is preparing to launch a new service under which it would monitor medical literature for reports of suspected adverse reactions from drugs containing certain active substances, and then submit the relevant case reports into the EudraVigilance system on behalf of drug companies.

You may also be interested in...

Roadmap On Improvements To EMA's Literature Monitoring Service Due By Year End

The European Medicines Agency will be looking for quick wins as well as long-term improvements when it revises its medical literature monitoring service. It will soon publish a roadmap for improving the service with details of when the changes might occur.

EMA Tackles Complexities Introduced By Literature Monitoring Service

The European Medicines Agency is looking at ways to improve and simplify its medical literature monitoring service, which has created new complexities for the generics pharmaceutical industry.

Global Regulators Seek Unified Approach To Remote Inspections

Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts